SYCP2 的表达是腔 A/B 型乳腺癌的一种新的预后生物标志物。

SYCP2 expression is a novel prognostic biomarker in luminal A/B breast cancer.

机构信息

Department of Breast Surgery, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Clinical Medicine, University of Electronic Science & Technology of China, Chengdu, 610072, Sichuan, PR China.

出版信息

Future Oncol. 2019 Mar;15(8):817-826. doi: 10.2217/fon-2018-0821. Epub 2018 Dec 4.

DOI:10.2217/fon-2018-0821

PMID:30511892

Abstract

AIM

To explore the prognostic value of synaptonemal complex protein-2 (SYCP2) in different subtypes of breast cancer. Patients & materials: In silico bioinformatic analysis was conducted using large databases.

RESULTS

SYCP2 was only significantly upregulated in luminal B tumors compared with the adjacent normal tissues. SYCP2 expression was an independent indicator of shorter overall survival in luminal A patients (hazard ratio: 2.269; 95% CI: 1.059-4.862; p = 0.035) and luminal B patients (hazard ratio: 2.546; 95% CI: 1.020-6.355; p = 0.045). Its expression was negatively correlated with the methylation status of multiple CpG sites (cg22214414, cg23241473 and cg07347645) in both luminal A and luminal B tumors.

CONCLUSION

Increased SYCP2 expression might be an independent indicator of shorter overall survival in both luminal A and luminal B patients.

摘要

目的

探讨联会复合体蛋白 2（SYCP2）在不同亚型乳腺癌中的预后价值。

患者和材料

使用大型数据库进行了计算机生物信息学分析。

结果

与相邻正常组织相比，SYCP2 仅在管腔 B 型肿瘤中显著上调。SYCP2 表达是管腔 A 型患者（危险比：2.269；95%置信区间：1.059-4.862；p=0.035）和管腔 B 型患者（危险比：2.546；95%置信区间：1.020-6.355；p=0.045）总生存期较短的独立指标。其表达与管腔 A 和管腔 B 型肿瘤中多个 CpG 位点（cg22214414、cg23241473 和 cg07347645）的甲基化状态呈负相关。